When to be concerned: red flags versus normal adjustment Most retatrutide diarrhea is an annoyance, not a danger
2040 EORTC item Q168: the psychometric performance of a single-item indicator of side-effect burden for people with cancer Tamara Jones 1 , Florian Zeman 2 , Michael Koller 2 , Andreia Moura 3 , Claire Piccinin 3 , Sandra Nolte 1 1 Person-Centred Research, Eastern Health Clinical School, Monash University, Melbourne, Australia, 2 Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 3 Quality of Life Department, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :2040 Aims Following the release of the US Food and Drug Administration (FDA) Guidance on core patient-reported outcomes in cancer clinical trials, there has been growing interest in using single items to measure treatment tolerability from the patients perspective
Makers of snack foods should take steps now to understand how these changes will affect their businesses, and consider reshaping their product portfolios to maintain future competitiveness
Schedule a consultation This article is for informational purposes only and does not constitute medical advice
The regulatory environment continues evolving, with increased scrutiny following widespread adoption of grey market GLP-1 agonists
This effect likely combines direct medication effects with the consequences of reduced sodium intake and weight loss
